Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spectral AI (Nasdaq: MDAI) will present at the H.C.
Rhea-AI Summary
Spectral AI (Nasdaq: MDAI) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026. CEO Vincent Capone and CFO David McGuire plan to highlight the company’s growth strategy and readiness for a 2026 commercial launch of its FDA De Novo–cleared DeepView® System for Burn Indication, which received clearance in May 2026. The presentation is scheduled for Monday, September 14, 2026 at 4:00 pm ET, with a live webcast available via the Investors section of Spectral AI’s website, and options to request one-on-one meetings through H.C. Wainwright or the company’s investor relations firm.
Positive
- None.
Negative
- None.
News Market Reaction – MDAI
In the Sep 1 session, MDAI declined 0.96%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 08 | Commercial leadership appointment | Positive | -0.6% | Named Darcy Bajko chief commercial officer to lead DeepView commercialization. |
| Jun 12 | Wound-care partnership | Positive | -2.1% | Partnered with wound-management foundation during Wound Healing Awareness Month. |
| Jun 11 | Conference participation | Positive | +1.6% | Presented DeepView at the British Burn Association annual conference. |
| Jun 01 | Annual meeting results | Positive | -1.9% | Stockholders approved proposals including share reservations under the purchase agreement. |
| May 26 | FDA clearance | Positive | -11.6% | Received FDA De Novo Classification authorizing U.S. commercial distribution. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged events averaged a -2.92% 24-hour price reaction, with four divergences and one alignment.
Key Terms
de novo clearance regulatory
multispectral imaging technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Highlight Growth Strategy and Readiness for 2026 Commercial Launch of FDA-Cleared DeepView® System for Burn Indication
DALLAS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Vincent Capone, Chief Executive Officer, and David McGuire, Chief Financial Officer, are scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14−16, 2026 in New York City.
“The receipt of FDA De Novo Clearance for our DeepView® System for Burn Indication in May 2026 was the culmination of years of hard work by our dedicated team and a defining moment in Spectral AI’s history,” said Vincent Capone, Chief Executive Officer. “We have made significant strides in evolving our company into a commercially focused enterprise, including expanding our leadership team, advancing label expansion initiatives, strengthening our relationships with government and commercial partners, and fortifying our financial position. We remain on track to achieve our first commercial sales by year end 2026.”
Conference Details
- Presentation Date & Time: Monday, September 14, 2026 at 4:00 pm Eastern Time.
- Live Webcast: Interested parties may access the live webcast of the presentation by visiting the Investors section of Spectral AI’s website at https://investors.spectral-ai.com/news-events/events.
- 1x1 Meetings: To request a one-on-one meeting, please contact your H.C. Wainwright representative or Spectral AI’s Investor Relations firm, The Equity Group.
- Additional Information: Please visit the conference website.
About the DeepView System
Spectral AI's DeepView System is a non-invasive, predictive medical device which combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within burn wounds. The DeepView System provides physicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “on track,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan, Managing Director
Devin.Sullivan@theequitygroup.com
Conor Rodriguez, Associate
Conor.Rodriguez@theequitygroup.com
